S.R.P. is a consultant for and has received research support from Ironshore Pharmaceuticals & Development, Inc., and has served as an expert witness for AstraZeneca. T.E.W. received grant support from NIH (NIDA); is a consultant for Alcobra, Ironshore Pharmaceuticals & Development, Inc., NIH (NIDA), Phoenix House and Bay Cove Human Services (Clinical Services), Neurovance/Otsuka, Sunovion, Tris, U.S. National Football League (ERM Associates), and U.S. Minor/Major League Baseball; has published a book, Straight Talk About Psychiatric Medications for Kids (Guilford Press); coedited books, ADHD in Children and Adults (Cambridge Press), Massachusetts General Hospital Comprehensive Clinical Psychiatry (Elsevier), and Massachusetts General Hospital Psychopharmacology and Neurotherapeutics (Elsevier); and is the co-owner of the Before School Functioning Questionnaire and has a licensing agreement with Ironshore Pharmaceuticals & Development, Inc. S.B. has participated in advisory boards for Curemark and Tris Pharma; and has received research support from Arbor Pharmaceuticals, Lundbeck, Neurim Pharmaceuticals, Pearson, Rhodes, Shire, Sunovion, and Supernus. V.K.A. has participated in advisory boards for Ironshore Pharmaceuticals & Development, Inc., Neos, Rho, and Shire; is a consultant for Ironshore Pharmaceuticals & Development, Inc.; and participates in speakers bureau for Lundbeck/Takeda. A.M. is a consultant for Ironshore Pharmaceuticals & Development, Inc. A.J.C. is a consultant and has received research support from Aevi Genomics, Akili Interactive, Alkermes, Allergan, Arbor Pharmaceuticals, Ironshore Pharmaceuticals & Development, Inc., Janssen, Kempharm, Lilly, Lundbeck, Neos Therapeutics, Neurovance, Novartis, Noven, Purdue, Rhodes Pharmaceuticals, Shire, Sunovion, Supernus, and Takeda; and is a speaker for Alkermes, Allergan, Arbor Pharmaceuticals, Janssen, Lilly, Lundbeck, Novartis, Shire, Sunovion, and Takeda. F.A.L. is a consultant or has participated in advisory boards for Ironshore Pharmaceuticals & Development, Inc., Neos, Novartis, Noven, Rhodes, Shionogi, Inc., Shire Canada, Shire Global, Shire U.S., Supernus, and Tris Pharma; and has received research support from Bristol-Myers Squibb, Cephalon, Ironshore Pharmaceuticals & Development, Inc., New River Pharmaceuticals, Novartis, Noven, Shire U.S., Pfizer, and Celltech Medeva. N.J.D. and B.I. are employees of Ironshore Pharmaceuticals & Development, Inc. F.R.S. is an employee of Ironshore Pharmaceuticals & Development, Inc.; and is a member of the Board of Directors for P2D Bioscience. J.H.N. is advisor/consultant for Akili Interactive, Alcobra, Arbor Pharmaceuticals, Cerecor, Enzymotec, Ironshore Pharmaceuticals & Development, Inc., KemPharm, Lundbeck, Medice, Neos, U.S. National Football League, NLS, Pearson, Rhodes, Shire, Sunovion, and Supernus; is a DSMB member of Sunovion; has received research grants from Enzymotec, Lundbeck, and Shire; and has received speaking honoraria (nonpromotional) from Shire and Teva.
PubMed
